| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Senior Vice President
1 company
Carl Walkey last filed a Form 4 in August 2022, as Senior Vice President at NGNE. From February 2021 to June 2021, the filings on record show 0 open-market purchases and 24 sales. Carl Walkey's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Carl Walkey a strong insider score of 94/100, based on 19 past trades. Over a 12-month horizon, all 19 of those trades were profitable, with an average 12-month return of +87.3%.
At the last filing, the largest reported position was 1,352,489 shares of NGNE. The NGNE filings lean toward selling, a net 34,850 shares.
Shares as reported in the last Form 4 for each company; the most recent is from August 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | NGNE Neurogene Inc. | Senior Vice President | Sell | 2,400 | $12.70 | $30,480.00 | -0.2% | |
| Feb 10, 2021 | NGNE Neurogene Inc. | Senior Vice President | Sell | 3,000 | $14.20 | $42,600.00 | -0.2% | |
| Feb 5, 2021 | NGNE Neurogene Inc. | Senior Vice President | Sell | 600 | $14.00 | $8,400.00 | - | |
| Feb 3, 2021 | NGNE Neurogene Inc. | Senior Vice President | Sell | 2,400 | $13.23 | $31,752.00 | -0.2% |